Iovance's AMTAGVI™ (lifileucel) Receives U.S. FDA

AMTAGVI is the first FDA-approved T cell therapy for a solid tumor cancer and first treatment option for advanced melanoma after anti-PD-1 and targeted...

Related Keywords

Philadelphia ,Pennsylvania ,United States ,Frederick Vogt ,Iovance Biotherapeutics ,Sara Pellegrino ,Jen Saunders ,Steven Rosenberg ,Alexandern Shoushtari ,National Cancer Institute Surveillance ,Melanoma Foundation ,Drug Administration ,Nasdaq ,Treatment Centers Atcs ,Exchange Commission ,European Medicines Agency ,Iovance Biotherapeutics Inc ,Investor Relations Corporate Communications ,Iovance Cell Therapy Center ,Surgery Branch ,Samanthar Guild ,National Cancer Institute ,Authorized Treatment Centers ,Interim Chief Executive Officer ,Response Evaluation Criteria ,Solid Tumors ,Important Safety Information ,Prescribing Information ,Melanoma Oncologist ,Cellular Therapist ,Memorial Sloan Kettering Cancer ,Jae Park ,Cellular Therapy Service ,Cancer Institute Surveillance ,End Results ,Accessed February ,Independent Review Committee ,Full Prescribing Information ,Patient Information ,Boxed Warning ,Important Safety ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Vice President ,Investor Relations ,Nasdaq Iova ,Nova ,